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Introduction 
Immune thrombocytopenic purpura (ITP) is an
acquired disease of children and adults defined by a low
platelet count in the absence of other clinically apparent
causes of thrombocytopenia.1 It is principally a disorder of
increased platelet destruction caused by antiplatelet
antibodies.  
In 1983 Salama et al reported platelet responses in
three of six Rh (D) positive patients treated with 400 to
2500 ug of anti-D (2).Anti-D is a plasma derived
immunoglobulin prepared from donors selected for a high
titer of Rho (D) antibody. The investigators suggested that
the rise in platelet count is due to competitive inhibition of
the macrophage binding of platelets by preferential
sequestration of immunoglobulin coated red blood cells.2
Important observations from published reports
include evidence of a dose response relationship,
reproducibility of responses, and efficacy of anti-D in Rh
(D) positive but not in Rh (D) negative subjects. Similarly
splenectomized patients had minimal or no responses.3 The
lower cost of anti-D plus the ease of administration make
anti-D therapy an attractive option as splenectomy sparing
therapy and as maintenance therapy in patients with chronic
ITP.4
Patients and Methods
This was a case series study which was carried out
from January 2000 to October 2002.
This study was conducted upon diagnosed patients
with Immune Thrombocytopenic Purpura. All patients of
ITP received Anti-D were included in one group and
patients who underwent splenectomy were included in the
second group. Patients with established diagnosis of ITP
were included in the study. All patients who had persistently
low platelet counts for at least six months , were blood
group Rh positive (anti-D group) had not undergone
splenectomy and were not receiving other forms of therapy
were included in the study. Post splenectomy patients and
patients with blood group other than Rh positive were
excluded.
Patients were eligible for inclusion if  they had a
diagnosis of acute or chronic ITP, had not undergone
splenectomy, their blood group was Rh positive (anti-D
group). All 23 patients included in the study fulfilled the
criteria mentioned above. All patients were analyzed for
demographic features including age, sex, age at the time of
diagnosis, clinical features at presentation, response to
initial treatment, rise in platelet counts following second
line treatment (IV anti-D) and persistence of response for 3
months. Response was defined as an increase in platelet
count to >50,000/cumm or doubling of pretreatment platelet
counts. Any adverse events with anti-D or splenectomy
were also recorded.
Anti-D (WinRho) was given at a dose of 50mg/kg.
The anti-D preparation was diluted in physiologic normal
saline and infused intravenously during a 15-30 minute
period on an outpatient basis. Patients were followed at
weekly intervals and any adverse events were recorded.
Complete blood count was performed at each outpatient
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Abstract
Objective: To determine the response to IV anti-D and its comparison with splenectomy as second line therapy
in refractory and relapsed cases of ITP, in the Aga Khan University Hospital, Karachi.
Methods: A total of 23 patients with chronic ITP were treated with either anti-D or splenectomy as second line
treatment. The patients were assessed for time to achieve a response to second line treatment, duration of
response and adverse events.
Results: There were 12 patients in the anti-D group and 11 in the splenectomy group. The mean platelet count
at presentation was 9,000/cumm. The mean age was 8.9 years and 13.0 years and the male to female ratio was
1:1 and 1:1.2 in anti-D and splenectomy group respectively. 54.5% of the patient in the anti-D group responded
compared to 81.8% in the splenectomy group. Median time to achieve a response was 7 days in the anti-D group
and 1 day in the splenectomy group. Mean time to relapse was 87.8 days in the anti-D group and 55.4 days in
the splenectomy group. No adverse events were recorded for any of the infusions of anti-D and none of the
patients had more than 0.5 gm /dl fall in the hemoglobin level following anti-D infusion.
Conclusion: It was thus concluded that Anti-D is a relatively safe, convenient and effective therapy for chronic
ITP and can be used as a splenectomy sparing agent when treatment is clinically indicated (JPMA 53:537;2003). 
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visit. Platelet counts were performed on EDTA specimens
by means of automated coulter STKS counter and
correlated with microscopic examination of peripheral
blood film.
All the data was analyzed using SPSS program
(statistical package for social sciences) version 10.0 by
Kaplan Maier analysis. 
Results
A total of 23 patients with chronic ITP were treated
with either anti-D or splenectomy as second line treatment.
There were 12 patients in the anti-D group and 11 in the
splenectomy group. The mean platelet count at presentation
was 9,000/cumm. The minimum follow-up after second line
treatment was 3 months. The mean age was 8.9 years and
13.0 years in the anti-D and splenectomy groups
respectively. The male to female ratio was 1:1 and 1:1.2 in
the anti-D and splenectomy groups respectively.
Petechaie and Epistaxis were found to be the most
common symptoms at presentation, seen in 65% and 26.1%
of the patients respectively.
Out of 23 patients, 21 patients were initially treated
with steroids. One patient received IVIG and one patient had
intravenous anti-D as first line treatment. The patient who
received IV anti-D as first line treatment achieved complete
remission and did not require any further therapy. Out of the
remaining 22 cases, 8/22 (36.3%) relapsed after tapering of
steroids and 14/22 (63.6%) were refractory to steroids. 
Anti-D was given in 11 patients as second line
treatment and 11 patients underwent splenectomy as second
line treatment. 54.5% of the patients in the anti-D group had
a response compared to 81.8% of the patients in the
splenectomy group.
Adverse Events
No adverse events were recorded for a total of 14
infusions of iv anti-D. None of the patients had more than
0.5 gm/dL fall in haemoglobin following anti-D infusion.
All patients had pre-treatment Hb levels of more than 10
gm/dL. In all cases the anaemia resolved spontaneously and
without specific therapy. 
Follow up of Patients who responded to Anti-D
Median time to achieve a response and mean time to
relapse is shown in table 1 and Kaplan Maier analysis is
shown in Figures 1 and 2.
Three out of 6 patients who initially responded to
Figure 1. Kaplan Maier survival function for anti-D and splenectomy.
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Table 1. Comparison of Anti-D and splenectomy for duration of
response.
Anti-D Splenectomy
Median time to response 7days 1.0 day
Mean time to relapse 87.8 days 55.4 days
Table 2. Results with anti-D in various studies.
Author (reference) No. of Response Duration of
patients rates (%) response
Andrew M (5) 25 72 5 weeks (1-24)
Michael D (6) 14 70 Not defined
Scaradavou A (7) 272 72 3 weeks in >50% of patients
Present study 12 58 12 weeks
Figure 2. Kaplan Maier survival function for time to relapse for anti-D and splenectomy.
anti-D relapsed. Two patients after splenectomy and one
after a second dose of anti-D.
Follow up of patients who were resistant to anti-D
Five out of 11 patients were non responders to an
initial infusion of anti-D. Three underwent splenectomy.
One received a second infusion of IV anti-D and remained
in complete remission till last follow up. One patient was
lost to follow up.
Discussion
Patients with ITP may require therapy to increase the
platelet counts for a variety of reasons and a number of
therapies are available to achieve that effect. However most
of these therapies are helpful on short term basis and many
have unacceptable side effects and high costs. Anti-D
appears to be promising since cost is low and side effects
are minor and rare. It can be given on outpatient basis
saving admission costs and considerable morbidity
associated with other second line therapies.
In our study the responses were rapid, had with
minimal toxicity a reasonable duration of effect.
However in comparison to splenectomy the response
rates were significantly lower and durable responses were
seen in only 50% of the patients as compared to more than
70% in the splenectomy arm.
Most of the available literature recommends anti-D
as splenectomy sparing therapy and our recommendation
would remain such too.  The comparison of response rates
and the duration of responses with international studies are
summarized in table 2.
Conclusion
It is concluded that anti-D is a relatively safe,
convenient and effective therapy for chronic ITP and can be
used as a splenectomy sparing agent when treatment is
clinically indicated. A 50 µg /kg dose of anti-D yields more
than 50% response rates with median duration of effect of
12 weeks.
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Abstract
Objective: Systemic Lupus Erythematosus (SLE) is an autoimmune process in which cutaneous lesions occur
in majority of patients. This study from Karachi, Pakistan was conducted to determine the pattern and prevalence
of such lesions in SLE in Pakistani patients.
Methods: One hundred ninety eight patients with SLE fulfilling the clinical and laboratory criteria of the American
Rheumatology Association were examined between 1986 and 2001` for the presence of cutaneous
manifestations. 
Results: Skin changes noted were: noncicatricial diffuse alopecia (22%), malar rash (31%), mucosal lesions
(20%), discoid eruptions (15%), photosensitivity (33%), vascular lesions (20%), pruritis (17%), and pigmentary
changes (22%). Peripheral gangrene,chronic ulcers, Raynauds phenomenon, urticaria, chilblains,
thrombophlebitis, palmar erythema, and erythema multiform were rare. Anti ANA and anti dsDNA were positive
in 93% and 83% patients respectively. 
Conclusion: A different clinical pattern was noted in our patients than reported previously (JPMA 53:539;2003).
